MET and non-small cell lung carcinoma: Dysfunction of the mesenchymal epithelial transition (MET) tyrosine kinase receptor and the MET pathway through MET amplifications or MET mutations are associated with the development of several solid tumors.1 The therapeutic strategy of inhibiting the MET pathway in MET-addicted solid tumors has been mostly best researched in NSCLC.